Additional Coverage:
New Weight Loss Pills and “Triple G” Drugs Revolutionize Treatment Landscape
The weight loss treatment landscape is undergoing a significant transformation, with the introduction of new GLP-1 (glucagon-like peptide-1) receptor agonist pills and the development of even more powerful injectable medications. What began with injectable predecessors like Wegovy has now expanded to oral formulations, with the Wegovy pill gaining rapid popularity since its FDA approval.
The Rise of Oral GLP-1s
The Wegovy pill, approved by the US Food and Drug Administration just ten weeks ago, is already being utilized by an estimated 400,000 Americans daily. Its swift adoption marks it as one of the fastest drug launches in history. This oral option appears to be attracting new users to GLP-1 therapies, with many prescriptions originating from general practitioners rather than specialized weight-loss doctors.
However, the Wegovy pill is not expected to be alone in the market for long. Eli Lilly is awaiting FDA approval for its own GLP-1 pill, orforglipron, anticipated to hit the market as early as next month.
A key advantage of orforglipron is its flexibility, allowing it to be taken at any time of day, with or without food or drink. In contrast, the Wegovy pill, a specially formulated oral version of semaglutide, requires specific timing: it must be taken first thing in the morning with a small amount of water, and no food, drinks, or other medications for at least 30 minutes.
Dr. Judith Korner, an endocrinologist and director of the Metabolic and Weight Control Center at Columbia University Vagelos College of Physicians and Surgeons, suggests that orforglipron’s less restrictive regimen will likely make it a preferred choice for patients seeking a GLP-1 pill. “If you don’t take the Wegovy pill just right, very little of the drug is actually absorbed,” Korner noted, highlighting the benefit of a more forgiving medication.
“Triple G” Drugs: A New Frontier in Efficacy
Beyond the convenience of pills, a new generation of even more potent injectable weight-loss medications is on the horizon. These drugs, dubbed “Triple G” because they mimic three hormones-GLP-1, GIP, and glucagon-are demonstrating unprecedented efficacy in clinical trials.
One such drug, retatrutide, developed by Eli Lilly, is a weekly injectable that has shown remarkable results. In December, clinical trial data revealed that retatrutide led to an average weight loss of up to 29% of participants’ body weight after 68 weeks in a study of individuals with knee osteoarthritis. New results released Thursday for type 2 diabetes patients showed an average A1C blood sugar reduction of 1.7% to 2% and average weight loss of up to 17% after 40 weeks, surpassing the efficacy of current options like Mounjaro.
Novo Nordisk, a competitor to Eli Lilly, is also developing its own “Triple G” drug, reporting an average weight loss of almost 20% in a mid-stage study. Additionally, Novo Nordisk’s higher-dose version of Wegovy received FDA approval on Thursday, showing an average weight loss of 21% over 72 weeks.
While these powerful new drugs offer significant promise for individuals who haven’t found sufficient benefit from existing therapies, doctors are also cautioning against their inappropriate use. Dr. Jody Dushay, an endocrinologist at Beth Israel Deaconess Medical Center and assistant professor at Harvard Medical School, emphasized that drugs like retatrutide may be most suitable for individuals with a body mass index above 45 or those who haven’t responded adequately to current treatments.
Both Dushay and Korner expressed concerns about the potential for these highly effective drugs to be used for “vanity” weight loss, particularly given the already visible trend of extreme body transformations in popular culture. Eli Lilly even released a commercial before the 2024 Oscars urging against such use.
Affordability and Insurance Coverage Remain Key Challenges
Despite the advancements in treatment options, cost and insurance coverage remain significant hurdles for many patients. The new weight-loss pills are priced at $149 per month for the lowest doses if patients pay out-of-pocket, a result of a deal struck with the Trump administration’s TrumpRx drug pricing initiative. While direct-pay options exist for injectable drugs, they still cost hundreds of dollars monthly.
Insurance coverage for weight-loss medications remains inconsistent. Blue Cross Blue Shield of Massachusetts, for example, recently announced it would cease covering GLP-1s for obesity, citing rising premium costs and suggesting patients consider direct purchases from manufacturers. Medicare has expanded coverage for some patients as part of the November deal but still does not cover weight-loss drugs for all who might benefit.
These affordability challenges are a driving factor for patients switching to more accessible options, such as the Wegovy pill. As more options become available, including orforglipron, potential price differentials will likely play a crucial role in patient and physician choices.